Background
The HER2/neu protein belongs to the family of epidermal growth factor receptors (EGFRs) and is known to be amplified in several neoplasms such as breast, salivary gland, stomach, kidney and lung. It is overexpressed in about 30% of breast cancer patients [
1‐
6]. The cytoplasmic domain of this intact tyrosine kinase receptor has been implied to generate normal mitogenic as well as transforming signals [
7], indicating its direct role in cell proliferation [
8]. HER2 expression has been correlated with poor prognosis in cancer patients by mechanisms such as impaired DNA repair [
9], angiogenesis [
10] and metastasis [
11]. The oncogenic property of HER2 can be well enunciated, but its role in chemotherapy is not clearly elucidated because of its obscured molecular mechanisms. Though there are effective approaches for targeting HER2 such as trastuzumab (herceptin), which is a specific antibody for HER2, it is associated with toxicity and/or resistance. This implies a need for the search of better therapeutic agents that can target HER2-positive cancer cells.
Doxorubicin (Adriamycin) is used to treat patients in the early stages of breast cancer. The normal dosage of doxorubicin usually ranges 40 to 60 mg/m
2. It is well established that a significant percentage of patients on doxorubicin therapy face a risk of cardiotoxocity at these doses [
12]. A lifetime cumulative dose of about 500 mg/m
2 has been associated with chronic cardiotoxicity [
13]. To avoid the drawbacks of doxorubicin, it is important to find novel therapies that can reduce its dose without compromising its therapeutic effects. It has been shown that doxorubicin can downregulate EGFR but not HER2 [
14]. The approach of combination therapies can help to enhance its efficacy in HER2-positive patients.
Interestingly in two clinical studies, it was observed that HER2-positive tumors responded better to the chemotherapy regimen than HER2-negative tumors [
15,
16]. Another study illustrated that cleavage of HER2 mediated apoptosis in cancer cells by inducing intrinsic apoptosis pathway [
17]. These studies indicated that the role of HER2 may be reciprocating between antiapoptotic and proapoptotic, but the conditions and agents that modulated this balance need to be identified. These studies also raised a question on the role of HER2 in cancer and provide rationale to study its possible dual role.
Various recent epidemiological studies have indicated that consumption of cruciferous vegetables such as garden cress, broccoli and so on, reduces the risk of breast cancer [
18,
19]. The glucosinolate-derived phenethyl isothiocyanates (PEITC) present in these vegetables has promising antitumorigenic effects, as mentioned by various studies [
19‐
23]. Clinical studies on PEITC for lung cancer are currently underway [
24]. These facts reinforce the importance and necessity of more preclinical studies required on this compound to expand and discover its true potential in breast cancer.
Our current studies establish the anticancer effects of PEITC in HER2-positive tumor cells. Our results show that the growth suppressive effects of PEITC in breast cancer cells were mediated by HER2 depletion in both in vitro and in vivo models and that HER2-expressing cells were more sensitive to PEITC-induced apoptosis. In addition, our study shows that in combination, PEITC can significantly enhance the apoptosis-inducing effects of doxorubicin. Our study provides a direction towards the mechanism of HER2-mediated sensitivity of cells to chemotherapy.
Methods
Cell culture
Human breast carcinoma cell lines MCF-7 and MDA-MB-231 were obtained from American Type Culture Collection (ATCC;
http://www.atcc.org) and were maintained in minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 5% penicillin/streptomycin/neomycin (PSN) and 0.01 mg/ml insulin and Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FBS and 5% PSN, respectively, unless otherwise stated. The HER2 overexpressing cells MDA-MB-231 (high HER2 (HH)) cells and their vector controls were kindly provided by Dr Patricia S Steeg (National Institutes of Health, Bethesda, MD, USA) and Dr Quentin Smith (Texas Tech University Health Sciences Center, Amarillo, TX, USA) and were maintained in DMEM supplemented with 10% FBS, 5% penicillin, streptomycin, neomycin solution and 300 μg/ml zeocin. HER2 was transfected in brain seeking subset of MDA-MB-231 cells. No significant difference was observed at molecular level in these cells and parental MDA-MB-231 cells. The MCF-7 overexpressing HER2 cells were kindly provided by Dr Huang Fei (Bristol-Myers Squibb Co., Princeton, NJ, USA) and were cultured in DMEM supplemented with 10% FBS and 5% PSN. The ATCC uses DNA fingerprinting (microsatellite analysis) for cell line authentication. All the cells used in this study were within 20 passages after receipt or resuscitation.
Cytotoxicity studies
Cells were plated at a density of 2,000 to 5,000 cells/well in 96-well plates, allowed to attach overnight and treated with different concentrations of PEITC (molecular weight 163.2; purity > 99%; Sigma Aldrich, St. Louis, MO, USA) for various time intervals. The cells were fixed with ice cold 10% trichloroacetic acid, washed and stained with sulforhodamine B dye. The optical density was measured in Tris base solution using a plate reader after washing the dye with 1% acetic acid solution as described by us previously [
25].
Annexin V-fluorescein isothiocyanate (FITC) apoptosis assay
The apoptosis assay was performed using a kit (BD Biosciences, San Jose, CA, USA) according to manufacturer's instructions. Approximately 0.3 × 106 cells were plated into six-well plates and left overnight for attachment. After treatment for 24 h with 0 to 15 μM PEITC, cells were harvested by trypsinization and suspended in phosphate-buffered saline (PBS) to a cell density of 1 × 106/ml. A total of 100 μl of binding buffer, 5.0 μl of Annexin V-FITC and 5 μl of propidium iodide were added to the suspension and incubated for additional 20 minutes at room temperature in the dark. Total sample volume was made up to 500 μl with binding buffer. Samples were incubated on ice in the dark and analyzed by flow cytometer after vortexing (Accuri C6, Ann Arbor, MI, USA).
Enzyme-linked immunosorbent assay (ELISA) apoptosis assay
Histone associated DNA fragmentation during apoptosis was analyzed using an ELISA kit (Roche Applied Science, Indianapolis, IN, USA). Approximately 1.0 × 10
4 cells were plated in each well in a 96 well plate and left overnight for attachment. After being treated with different concentrations of PEITC for 24 h, cells were processed according to the manufacturer's instructions and as described by us previously [
26].
Hydrogen peroxide determination
Cells were plated in a six-well plate at a density of 0.3 × 10
6 cells per well and were allowed to attach overnight. After 24 h of treatment with PEITC, cells were harvested and lysed as described under western blotting analysis to collect and estimate the protein. The protein was transferred to 96 well plates at a concentration of 5 μg per well. The hydrogen peroxide (H
2O
2) content was determined using the Quantichrom (Bioassay Systems, Hayward, CA, USA) peroxide assay kit as per the manufacturer's instructions and described by us [
27].
Mitochondrial membrane potential
Cells were plated at a density of 0.3 × 10
6 cells/well in a six-well plate, allowed to attach overnight and treated with 10 μM PEITC for 24 h. Prior to collection, cells were incubated with 100 nM tetramethylrhodamine (TMRM) (Life Technologies, Grand Island, NY, USA) for 20 minutes. Cells were washed with PBS, resuspended in fluorescence-activated cell sorting (FACS) running buffer and analyzed by flow cytometry (Accuri C6) as described by us [
27].
Western blot analysis
The cells were treated with varying concentrations of PEITC (5, 10 and 15 μM) for 24 h. In a time-dependent study, cells were treated with 10 μM PEITC for 0, 1, 2, 4, 8, 12, 16, 24 and 48 h. In another experiment, MDA-MB-231 cells were treated with 10 mM Tiron for 1 h prior to treatment with 10 μM PEITC for 24 h. Whole cell lysates were prepared using 4% (w/v) CHAPS buffer (6 M urea, 2 M thiourea, 10 mM Tris pH 7.4) while tumor lysates were prepared by homogenizing the tumors in PBS. Control and treated protein was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and the segregated protein was transferred on a polyvinylidene fluoride (PVDF) membrane. The membrane was developed as described by us previously using primary antibodies specific to human HER2 (Abcam, Cambridge, MA, USA; 1:700), EGFR (Cell Signaling, Danvers, MA, USA; 1:1000), phosphorylated signal transducer and activator of transcription 3 (p-STAT3) (Y705) (Cell Signaling, Danvers, MA, USA; 1:1000), STAT3 (Cell Signaling, Danvers, MA, USA; 1:1000), BIM (Cell Signaling, Danvers, MA, USA; 1:2000), BCL-2-associated × (BAX) (Cell Signaling, Danvers, MA, USA; 1:2000), B-cell lymphoma-extra large (BCL-XL) (Cell Signaling, Danvers, MA, USA; 1:1000), X-linked inhibitor of apoptosis protein (XIAP) (Cell Signaling, Danvers, MA, USA; 1:1000), cleaved caspase 3 (Cell Signaling, Danvers, MA, USA; 1:1000), cleaved poly-ADP ribose polymerase (PARP) (Cell Signaling, Danvers, MA, USA; 1:1000) and actin (Sigma Aldrich, St. Loius, MO, USA; 1:10,000) [
28,
29].
Mitochondria-free cytosolic fractionation
The cell fractionation was performed using the mitochondrial extraction kit (Pierce, Rockford, IL, USA) as per the manufacturer's instructions. The cells were plated at density of 5 × 106 cells per 150 mm petri dish, left at incubation for attachment overnight and then treated with 10 μM PEITC for 24 h. Cells were harvested using trypsin after treatment and processed as per manufacturer's instructions.
HER2 silencing using HER2 small interfering (si)RNA
Approximately 0.3 × 106 cells were plated in a six-well plate and left overnight for attachment. The next day cells were transfected with HER2 siRNA or scrambled siRNA (Cell Signaling, Danvers, MA, USA) as per manufacturer's instructions using siPORT transfection reagent. After 2 days of transfection, cells were treated with 10 μM PEITC for 24 h, and the cell lysate was used for western blotting.
HER2 overexpression by transient transfection
HER2 plasmid with pcDNA3 vector backbone was obtained from Addgene. Approximately 0.3 × 106 cells per well were plated in six-well plates and left overnight for attachment. The next day cells were transfected with 5 μg HER2 plasmid using Xfect Transfection reagent (Clontech, Mountainview, CA, USA) as per manufacturer's instructions. After 2 days of transfection, cells were treated with 10 μM PEITC. After 24 h of treatment, cell lysate was analyzed by western blotting.
Immunofluorescence
Sections of approximately 20 micron were obtained from snap frozen tumor tissues for tumor analysis. The sections were gently placed on positively charged slides, fixed using 4% paraformaldehyde and blocked with 5% goat serum for 60 minutes as described by us previously [
30]. For immunostaining cells were plated in a six-well plate on a coverslip at a density of 0.1 × 10
6 cells/well, allowed to attach overnight and treated with 10 μM PEITC for 24 h. Cells were rinsed twice with PBS for 5 minutes each, fixed with an ice cold mixture of acetone and methanol (1:1), rinsed with PBS and blocked with 5% goat serum for 60 minutes. Eventually, cells and tumor sections were probed with antibodies specific to HER2, p-STAT3 (Y705) and cleaved caspase 3 overnight at 4°C, followed by incubation with Alexa Fluor 488 (anti-mouse) and Alexa Fluor 594 (anti-rabbit) secondary antibodies for 1 h by gentle rocking at room temperature. After washing the cells with PBS three times, the nucleus was counterstained with DRAQ 5 (Axxora LLC, San Diego, CA, USA). Cells and tumor sections were photographed under microscope (Olympus Inc.) after coverslips were mounted on the slides.
Tumor therapy model
Female SCID/NOD mice (4 to 6 weeks old) were obtained from Charles River (Wilmington, MA, USA) and maintained under specific pathogen-free conditions. The use of SCID/NOD mice and their treatment was approved by the Institutional Animal Care and Use Committee (IACUC), Texas Tech University Health Sciences Center, and the experiments were conducted in strict compliance with the regulations. Mice were given antioxidant-free AIN-76A special diet (TestDiet, Richmond, IN, USA) 1 week before starting the experiment. Exponentially growing MDA-MB-231 (HH) cells were harvested, washed twice with PBS and resuspended in 1:1 PBS/matrigel at a density of 50 × 10
6 cells per ml. A suspension of 0.1 ml containing 5 × 10
6 cells was injected in the right flank subcutaneously in the recipient mouse. Tumor volumes were measured three times a week (Monday, Wednesday and Friday), and animal weights were taken twice a week (Monday and Friday) as described by us previously [
26,
30]. The tumor volumes were calculated from tumor lengths and widths using the formula (length × (width)
2/2) [
31]. When the tumors reached a size of about 150 mm
3, mice were randomly segregated into two groups with ten mice in each group. Test group of mice received 12 μmol PEITC (81 mg/kg) in PBS by oral gavage every day until day 35, whereas control mice received vehicle alone. No obvious signs of toxicity or discomfort were observed in the mice orally gavaged over the time. Mice were killed on day 35 by CO
2 overdose, and death was confirmed by cervical dislocation in accordance with IACUC guidelines. The tumors were removed aseptically from each mouse and were snap frozen in liquid-nitrogen after taking the tumor weights for western blot analysis and immunofluorescence analysis.
Combination of doxorubicin and PEITC
The effect of PEITC in combination with conventional chemotherapy agent doxorubicin (purity > 98%, Sigma Aldrich, St. Loius, MO, USA) was evaluated in MDA-MB-231 and MDA-MB-231 (HH) cells. In brief, cells were treated with 4 μM PEITC and 3 μM doxorubicin for 24 h and analyzed by sulforhodamine B cell survival assay and western blotting as described above.
Statistical analysis
The statistical calculations and analysis were performed using Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA). Results represent means ± SD or SEM of at least three independent experiments. Data was analyzed by Student's t test. Differences were considered statistically significant at P < 0.05.
Discussion
Our results indicated that PEITC treatment considerably suppressed the viability of MCF-7 and MDA-MB-231 breast cancer cells. The reduced viability of these cells was associated with HER2/EGFR downregulation. In addition PEITC treatment reduced the expression and the phosphorylation of STAT3. Overexpressing HER2 using HER2 plasmid enhanced the cytotoxic potential of PEITC in these cells. However, silencing HER2 using siRNA blocked the apoptosis induced by PEITC treatment relative to the cells with constitutive levels of HER2. Stable overexpression of HER2 in these cells made the cells more sensitive to the cytotoxic effects of PEITC as indicated by reduced IC50 values. Furthermore, our results indicate that PEITC treatment induced hydrogen peroxide production in breast cancer cells leading to mitochondrial membrane depolarization. In line with hydrogen peroxide production and mitochondrial membrane depolarization, PEITC treatment resulted in the release of cytochrome c into the cytosol, leading to the activation of the caspase 3 cascade. Oral administration of PEITC significantly suppressed the growth of breast tumors in SCID/NOD mice. Tumors from PEITC mice demonstrated reduced expression of HER2, EGFR, STAT3, BCL-XL and XIAP, and increased cleavage of BIM, caspase 3 and PARP indicating apoptosis. To the best of our knowledge, our study for the first time implicated the probable role of HER2 in sensitizing breast cancer cells to PEITC-induced apoptosis in vitro and in vivo.
HER2 is a tyrosine kinase associated with poor prognosis in breast cancer [
2]. Substantial evidence indicates its direct role in tumor progression by promoting migration, invasion, antiapoptotic pathways [
36] and drug resistance [
9]. Under normal conditions HER2 plays an important role in the development of mammary glands and lactation during parturition [
37], while deregulation of HER2 leads to the development and progression of breast cancer [
38]. Since 1989 efforts have been made to develop therapeutics for HER2-positive breast tumors [
39,
40]. Trastuzumab (herceptin), a US Food and Drug Administration (FDA)-approved monoclonal antibody against HER2, was apparently effective in the treatment of HER2-positive tumors [
41,
42]. However, patients with HER2-positive tumors frequently present primary or secondary resistance to this agent [
43]. Also, a significant number of patients show moderate to severe toxicity with trastuzumab [
44‐
46]. These detrimental side effects of current targeted therapies raise a need for newer and better therapeutic agents for targeting HER2. Our results show efficacy of PEITC towards HER2-expressing breast cancer cells. Notably, previous studies have shown that PEITC is not toxic to normal cells [
47]. Although induction of cell death has been shown by PEITC in MCF-7 cells [
48], the effect of PEITC on HER2 has not been reported so far. To ascertain the specificity of PEITC for HER2, we tested the effect of PEITC in two prototype and syngeneic breast cancer cell lines MDA-MB-231, MDA-MB-231 (HH), MCF-7 and MCF-7 (HH), which have varying levels of HER2. Interestingly we observed increased sensitivity of the cells with higher levels of HER2 towards PEITC. Some previous studies have shown reduced efficiency of chemotherapeutic drugs due to HER2 overexpression [
13].
HER2 functions through homodimerization and heterodimerization with other EGFR family receptors to activate further downstream effectors [
12]. Some studies indicate the role of STAT3 in EGFR signaling in various cancers [
49,
50]. Our current study also indicated EGFR inhibition in breast cancer cells by PEITC treatment. Furthermore, inhibition of STAT3 expression and phosphorylation by PEITC treatment in our model indicated the inhibition of survival pathways in breast cancer cells. In agreement with our studies, PEITC has been shown to suppress STAT3 activation in prostate cancer cells [
51]. Silencing and overexpression of HER2 showed changes in STAT3 phosphorylation. Though there is no established correlation yet between HER2 and STAT3, our results indicated that HER2 might be regulating STAT3. Detailed studies are needed to further confirm and establish a relationship between HER2 and STAT3.
During the intrinsic mitochondrial death pathway, cytochrome c is released from the mitochondria into the cytosol due to a decrease in mitochondrial membrane potential [
52]. Mitochondrial membrane potential is compromised as a result of ROS generation. Our results show that PEITC treatment caused ROS generation and mitochondrial depolarization, resulting in the release of cytochrome c, hence activating caspase 3 mediated apoptosis in agreement with the outcome of other study [
53]. Antioxidant Tiron significantly blocked the decrease in HER2 expression and apoptosis by PEITC treatment suggesting the regulation of HER2 by ROS. A recent study suggested that certain genes that are upregulated in HER2 tumors were activated during oxidative stress [
48]. Interestingly, the extent of ROS generation and mitochondrial depolarization by PEITC was much higher in HER2 overexpressing cells as compared to parent cells. These observations suggest a link between ROS, HER2 and mitochondrial damage by PEITC in breast cancer cells. Nonetheless, further studies are needed to correlate HER2 and mitochondrial functions. A recent study indicated the involvement of mitochondrial STAT3 in inhibiting ROS production via mitochondrial electron transport chain (ETC) complex I [
54]. We also observed inhibition of mitochondrial STAT3 by PEITC treatment in breast cancer cells (data not shown). It was not clear at this point whether ROS generation by PEITC in our model was through the interaction of mitochondrial STAT3 with ETC complex I and needs further investigation. In our studies we also observed significant inhibition of XIAP by PEITC treatment. XIAP is a known inhibitor of apoptosis [
55], and transmits survival signals in breast cancer cells [
56]. Second mitochondria-derived activator of caspases (Smac) is a known repressor of XIAP and is elevated during apoptosis. We did not observe any significant change in the expression of Smac by PEITC treatment indicating Smac-independent suppression of XIAP in our model.
Oral administration of 12 μmol PEITC significantly suppressed the growth of breast tumor
in vivo. In a recent study oral administration of 10 μmol/kg PEITC in rats resulted in the peak plasma concentration of 9.2 ± 0.6 μM PEITC [
57]. Notably, the IC
50 of PEITC in HER2 overexpressing cells in our model was less than 5 μM. These results indicate that the therapeutic concentration of PEITC can be achieved clinically in human patients.
Doxorubicin has been used for breast cancer treatment for a long time, but its use has been associated with dose-related acute and chronic toxicity in most of the patients. Several measures have been taken to reduce its toxicity, such as combining it with other chemotherapeutic agents to reduce its dose without compromising its efficacy. Interestingly, our results showed that the cytotoxic effects of doxorubicin can be enhanced by concomitant use of PEITC. Combination of doxorubicin with PEITC effectively suppressed HER2 and STAT3 phosphorylation in breast cancer cells, resulting in enhanced apoptosis as compared to individual treatments respectively. These observations have clinical relevance as our data suggests that the effect of doxorubicin at low doses can be increased by PEITC in HER2-expressing breast cancer cells, which show poor response to doxorubicin therapy in general. Detailed in vitro and in vivo studies are required to establish this association.
Taken together, our results indicated that (i) HER2 is a potential molecular target of PEITC in breast cancer cells in vitro and in vivo and (ii) PEITC has a potential to enhance the cytotoxic effects of doxorubicin. Our study suggests a unique specificity of PEITC towards HER2-overexpressing breast cancer cells, indicating that PEITC could be beneficial to a subset of patient population overexpressing HER2.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
PG was responsible for designing the study, performing the experiments and writing the first draft of the manuscript. SKS was responsible for designing the study, analyzing the data and writing the manuscript. All authors read an approved the final manuscript.